Disease Progression in Women With X-linked Adrenoleukodystrophy

Recruiting now

Conditions studied: X-linked Adrenoleukodystrophy

In brief

Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.

Key facts

Study ID

NCT06178120

Run by

Minoryx Therapeutics, S.L.

People needed

40

Starts

2024-01-02

Expected to finish

2027-06-01

Last updated by the study team

2024-01-31

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women aged 18 years old or older.
• Diagnosis of X-linked ALD based on genetic testing, altered VLCFA levels, or family history.
• Willing to undergo annual follow-up visits, including brain and spinal cord MRI scans.
• Provision of written informed consent.
• Affiliation or beneficiary of a French social security system or of such a regime.

You may not qualify if…

• Any condition that in the opinion of the investigator are likely to adversely affect the study participation, interfere with study compliance, or confound the study results.
• Under treatment or previous treatment with leriglitazone.
• Pregnant or lactating women.
• Subjects benefiting from laws aimed at protecting vulnerable adults: subjects being deprived of liberty by judicial or administrative decision, subjects under guardianship.
• Participation in an interventional clinical trial.

Where it is running

• Paris Brain Institute (ICM) Centre Hospitalier Universitaire Pitié Salpêtrière — Paris, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.